CME/CE
Your professional development is critical to the care of your patients. Stay on top of the latest treatments and information with ReachMD's CME activities. Our topics span cardiology, diabetes, oncology, women's health and more. And our CME library is continuously growing, every quarter.
331-345 of 959
Applications of Emerging Data in Resectable NSCLC
MinuteCE®Applications of Emerging Data in Resectable NSCLC
The Current Therapeutic Landscape in Unresectable Stage III NSCLC
MinuteCE®The Current Therapeutic Landscape in Unresectable Stage III NSCLC
Strategies in EGFR-mutated Unresectable Stage III NSCLC
MinuteCE®Strategies in EGFR-mutated Unresectable Stage III NSCLC
Finding the Optimal Treatment for EGFR-mutated Metastatic NSCLC
MinuteCE®Finding the Optimal Treatment for EGFR-mutated Metastatic NSCLC
MET and Other Emerging Targets in Metastatic NSCLC
MinuteCE®MET and Other Emerging Targets in Metastatic NSCLC
- advertisement
Emerging Therapeutic Developments in Non-Targetable Metastatic NSCLC
MinuteCE®Emerging Therapeutic Developments in Non-Targetable Metastatic NSCLC
Data Driving Recent Guideline Updates in Neoadjuvant Therapy for Resectable Melanoma
MinuteCE®Data Driving Recent Guideline Updates in Neoadjuvant Therapy for Resectable Melanoma
Clinical Implications of Neoadjuvant Therapy Guideline Updates in Resectable Melanoma
MinuteCE®Clinical Implications of Neoadjuvant Therapy Guideline Updates in Resectable Melanoma
Efficacy and Safety Outcomes for Adjuvant Immunotherapy Driving Guideline Recommendations for Stage IIB/IIC Melanoma
MinuteCE®Efficacy and Safety Outcomes for Adjuvant Immunotherapy Driving Guideline Recommendations for Stage IIB/IIC Melanoma
Efficacy and Safety Outcomes for Adjuvant Immunotherapy Driving Guideline Recommendations for Stage III/IV Melanoma
MinuteCE®Efficacy and Safety Outcomes for Adjuvant Immunotherapy Driving Guideline Recommendations for Stage III/IV Melanoma
Implementing Guideline-Concordant Care for a Patient With Newly Diagnosed Stage III Melanoma
MinuteCE®Implementing Guideline-Concordant Care for a Patient With Newly Diagnosed Stage III Melanoma
- advertisement
Data Driving Preferred Guideline Recommendations in First-Line Therapy for Metastatic Melanoma
MinuteCE®Data Driving Preferred Guideline Recommendations in First-Line Therapy for Metastatic Melanoma
Implementing Guideline-Concordant Care for a Patient With Newly Diagnosed BRAF-Mutant Stage IV Melanoma
MinuteCE®Implementing Guideline-Concordant Care for a Patient With Newly Diagnosed BRAF-Mutant Stage IV Melanoma
Clinical Data Prompting Guideline Updates for Subcutaneous ICIs in Melanoma
MinuteCE®Clinical Data Prompting Guideline Updates for Subcutaneous ICIs in Melanoma
